Larger cohorts of patients are needed to overcome this limitation that integrate biochemical (e.g., protein concentration) and genetic (e.g., polymorphisms) information, perhaps accounting for epistatic interactions between this pentraxin and other pathogenetic drivers of DR (and AMD), including FGFs (and complement proteins). The gene discussed is VTN; the disease is age-related macular degeneration.